This review focuses on the cell-surface pro-HGF activation system in urological cancers, including prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) of bladder, and summarizes its significance in the progression of cancer. This evidence concerns the gene HGF and pachyonychia congenita.